The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Levodopa. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triflupromazine. Zuclopenthixol may decrease the stimulatory activities of Methamphetamine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexbrompheniramine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with clomethiazole. The serum concentration of Zuclopenthixol can be increased when it is combined with Clemastine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indiplon. The serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir. The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol. Zuclopenthixol may decrease the stimulatory activities of Mephentermine. Dasatinib may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Zuclopenthixol. Amantadine may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Quetiapine is combined with Zuclopenthixol. Lenvatinib may increase the QTc-prolonging activities of Zuclopenthixol. The serum concentration of Zuclopenthixol can be decreased when it is combined with Rifampicin. Histrelin may increase the QTc-prolonging activities of Zuclopenthixol. The serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amperozide. Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiagabine. The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol. The metabolism of Zuclopenthixol can be decreased when combined with Lumefantrine. The serum concentration of Zuclopenthixol can be increased when it is combined with Rucaparib. Galantamine may increase the QTc-prolonging activities of Zuclopenthixol. Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dezocine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Norflurane. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Drotebanol. Formoterol may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluspirilene. The risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluticasone propionate. Dolasetron may increase the QTc-prolonging activities of Zuclopenthixol. The metabolism of Zuclopenthixol can be decreased when combined with Tipranavir. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Remoxipride. Diphenhydramine may increase the QTc-prolonging activities of Zuclopenthixol. The metabolism of Zuclopenthixol can be decreased when combined with Cholecalciferol. The risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol. Zuclopenthixol may decrease the stimulatory activities of Hydroxyamphetamine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexmedetomidine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Melatonin. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fludiazepam. The serum concentration of Zuclopenthixol can be increased when it is combined with Fluconazole. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dextropropoxyphene. Tamoxifen may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate. Nortriptyline may increase the QTc-prolonging activities of Zuclopenthixol. Imipramine may increase the QTc-prolonging activities of Zuclopenthixol. Zuclopenthixol may decrease the stimulatory activities of Diethylpropion. Zuclopenthixol may decrease the stimulatory activities of Amphetamine. The risk or severity of adverse effects can be increased when Milnacipran is combined with Zuclopenthixol. Desflurane may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cinchocaine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Meclizine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Enflurane. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorzoxazone. The risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol. The serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sepranolone. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Melperone. The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zuclopenthixol. Tizanidine may increase the QTc-prolonging activities of Zuclopenthixol. Zuclopenthixol may increase the sedative activities of Metyrosine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Bromperidol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzyl alcohol. Flecainide may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lofentanil. The serum concentration of Zuclopenthixol can be increased when it is combined with Olaparib. The serum concentration of Zuclopenthixol can be increased when it is combined with Diltiazem. The risk or severity of adverse effects can be increased when Paliperidone is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etomidate. Paroxetine may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene. The metabolism of Zuclopenthixol can be decreased when combined with Bupropion. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Acepromazine. The serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib. The metabolism of Zuclopenthixol can be decreased when combined with Promazine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertindole. Degarelix may increase the QTc-prolonging activities of Zuclopenthixol. The serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Glutethimide. Dabrafenib may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dihydromorphine. The risk or severity of adverse effects can be increased when Quazepam is combined with Zuclopenthixol. The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Bromocriptine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Entacapone. The serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine. Sulfamethoxazole may increase the QTc-prolonging activities of Zuclopenthixol. The serum concentration of Zuclopenthixol can be increased when it is combined with Crizotinib. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pizotifen. The risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol. Zuclopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. The serum concentration of Zuclopenthixol can be decreased when it is combined with Primidone. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorprothixene. The risk or severity of adverse effects can be increased when Estazolam is combined with Zuclopenthixol. The serum concentration of Zuclopenthixol can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Canertinib. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Opium. The risk or severity of adverse effects can be increased when Gabapentin is combined with Zuclopenthixol. Perampanel may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dapoxetine. Zuclopenthixol may decrease the stimulatory activities of Pseudoephedrine. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol. The metabolism of Zuclopenthixol can be decreased when combined with Betaxolol. The metabolism of Zuclopenthixol can be decreased when combined with Thioridazine. The serum concentration of Zuclopenthixol can be increased when it is combined with Ziprasidone. The risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Cabergoline is combined with Zuclopenthixol. The metabolism of Zuclopenthixol can be decreased when combined with Eliglustat. The serum concentration of Zuclopenthixol can be increased when it is combined with Fluvoxamine. The risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol. Zuclopenthixol may increase the QTc-prolonging activities of Ivabradine. Arformoterol may increase the QTc-prolonging activities of Zuclopenthixol. The serum concentration of Zuclopenthixol can be increased when it is combined with Dihydroergotamine. The serum concentration of Zuclopenthixol can be increased when it is combined with Clotrimazole. Metoclopramide may increase the QTc-prolonging activities of Zuclopenthixol. The serum concentration of Zuclopenthixol can be decreased when it is combined with Fosphenytoin. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chloral hydrate. Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The risk or severity of adverse effects can be increased when Oxazepam is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipamperone. The risk or severity of QTc prolongation can be increased when Domperidone is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brompheniramine. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methsuximide.